Paul J Mosca

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi When a chance to cut is not a chance to cure: a future for palliative surgery?
    Paul J Mosca
    Ann Surg Oncol 18:3235-9. 2011
  2. ncbi Melanoma arising in a skin graft
    Jennifer G Hall
    Department of General Surgery, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27710, USA
    Ann Plast Surg 54:92-6. 2005
  3. ncbi Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
  4. ncbi Proteomics for monitoring immune responses to cancer vaccines
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
    Curr Opin Mol Ther 5:39-43. 2003
  5. ncbi Dendritic cell maturation in active immunotherapy strategies
    Michael A Morse
    Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:35-43. 2002
  6. doi Can surgeons improve survival in stage IV melanoma?
    Paul J Mosca
    Department of Surgery, Lehigh Valley Hospital, Allentown, PA, USA
    J Surg Oncol 97:462-8. 2008
  7. ncbi Current status of dendritic cell immunotherapy of malignancies
    Paul J Mosca
    Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Int Rev Immunol 22:255-81. 2003
  8. ncbi Immune monitoring
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Treat Res 123:369-88. 2005
  9. ncbi Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
  10. ncbi Surgical management of cutaneous melanoma: current practice and impact on prognosis
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Adv Surg 38:85-119. 2004

Collaborators

Detail Information

Publications17

  1. ncbi When a chance to cut is not a chance to cure: a future for palliative surgery?
    Paul J Mosca
    Ann Surg Oncol 18:3235-9. 2011
    ....
  2. ncbi Melanoma arising in a skin graft
    Jennifer G Hall
    Department of General Surgery, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27710, USA
    Ann Plast Surg 54:92-6. 2005
    ..This exceptional presentation of cutaneous melanoma is discussed to highlight key principles of skin grafting in relation to the management of malignant melanoma...
  3. ncbi Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
    ..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
  4. ncbi Proteomics for monitoring immune responses to cancer vaccines
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
    Curr Opin Mol Ther 5:39-43. 2003
    ..Advances in miniaturization and automation may also permit characterization of the immune response more rapidly and from smaller amounts of biological material than is possible with existing assay systems...
  5. ncbi Dendritic cell maturation in active immunotherapy strategies
    Michael A Morse
    Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:35-43. 2002
    ....
  6. doi Can surgeons improve survival in stage IV melanoma?
    Paul J Mosca
    Department of Surgery, Lehigh Valley Hospital, Allentown, PA, USA
    J Surg Oncol 97:462-8. 2008
    ..Incorporating these results into new approaches using multimodality treatment may enhance survival in patients with stage IV melanoma...
  7. ncbi Current status of dendritic cell immunotherapy of malignancies
    Paul J Mosca
    Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Int Rev Immunol 22:255-81. 2003
    ..Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer...
  8. ncbi Immune monitoring
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Treat Res 123:369-88. 2005
    ..It should be the goal and expectation that this rational approach to immune monitoring will allow the critical appraisal of the most promising vaccine candidates in the context of pivotal, multi-center trials...
  9. ncbi Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
    ....
  10. ncbi Surgical management of cutaneous melanoma: current practice and impact on prognosis
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Adv Surg 38:85-119. 2004
  11. ncbi Immunotherapy of surgical malignancies
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina, USA
    Curr Probl Surg 41:15-132. 2004
  12. ncbi Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma
    Katherine E Posther
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg Oncol 13:728-39. 2006
    ..Desmoplastic melanoma (DM) has been associated with higher local recurrence rates than other types of cutaneous melanoma. Current controversies regarding locoregional treatment strategies warrant further investigation...
  13. ncbi Dendritic cell vaccines
    Paul J Mosca
    Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 12:4050-60. 2007
    ..The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations...
  14. ncbi Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand
    Paul J Mosca
    Department of General and Thoracic Surgery, Pathology, Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Leukoc Biol 72:546-53. 2002
    ..The ability to generate phenotypically mature, IL-12-producing DC1 from peripheral blood mononuclear cells mobilized by Flt3L will have important implications for the development of effective cancer immunotherapy strategies...
  15. doi A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US
    Georgia M Beasley
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 208:706-15; discussion 715-7. 2009
    ..Establishing response and toxicity to ILI as compared with hyperthermic isolated limb perfusion is important for optimizing future regional chemotherapeutic strategies in melanoma...
  16. doi Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI
    James C Padussis
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Int J Hyperthermia 24:239-49. 2008
    ..This paper reviews progress in these two key areas of active investigation...
  17. ncbi Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response
    Thomas A Aloia
    Division of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Arch Surg 140:1115-20. 2005
    ..Analysis of multiple clinical and pathological factors in patients undergoing therapeutic hyperthermic isolated limb perfusion for extremity melanoma can identify variables with prognostic significance...